CardieX Limited’s (ASX: CDX) subsidiary ATCOR has been granted a new patent by the European Patent Office (EPO) in relation to the intellectual property (IP) for the company’s proprietary SphygmoCor technology used in cuff-based blood pressure devices.
EPO Patent Number EP2566387 further protects the Company’s IP in relation to the measurement of a whole central blood pressure waveform with cardiovascular features using a brachial cuff.
The patent specifically covers non-invasively estimating the heart’s pressure and pressure waveform with features related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure.
CEO & Managing Director, Craig Cooper, said the patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease which otherwise would require an invasive procedure.
Examining officers from the EPO specifically referenced the substantial differences in respect of any other existing patents when granting the new patent to ATCOR, demonstrating the unique nature of the technology.
The granting of the European patent follows similar patents already granted to the company in the United States and Japan, with the new European patent in force until 2034.
ATCOR’s SphygmoCor technology is the global standard for the non-invasive measurement of arterial stiffness in medical settings with all “Top 20 USA Hospitals” using the technology, over 4500 installations worldwide, and used by major pharmaceutical companies and research institutions such as The Mayo Clinic, GlaxoSmithKline, AstraZeneca, Bayer, Scripps, Johns Hopkins, and Stanford University.
ATCOR currently sells the XCEL central blood pressure device and has a partnership with SunTech Medical in relation to the Oscar 2 ABPM device – both of which incorporate ATCOR’s SphygmoCor technology and brachial cuff IP.
The company also recently announced a new partnership with Andon for the development of a home-based BP monitoring device with advanced cardiovascular vital signs features.
We are very pleased to be granted this new patent to protect our IP in Europe,” Mr Cooper said.
“Of great significance is the findings of the examining officers from the EPO which were similar to the findings we received from examiners in the US in 2016 – that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology.”